MS
44
-2
MAT
25
-5
PCAR
25
8
CF
27
-6
HUM
31
11
COST
29
-2
PEP
27
-5
AMAT
19
-2
CHD
32
-8
HIG
44
-2
NWS
56
9
DGX
35
-2
RL
42
-6
TGT
31
-3
PRU
30
-6
FTI
25
-5
KSS
12
-3
EA
26
-2
PHM
31
-11
MCD
44
-2
MS
44
-2
MAT
25
-5
PCAR
25
8
CF
27
-6
HUM
31
11
COST
29
-2
PEP
27
-5
AMAT
19
-2
CHD
32
-8
HIG
44
-2
NWS
56
9
DGX
35
-2
RL
42
-6
TGT
31
-3
PRU
30
-6
FTI
25
-5
KSS
12
-3
EA
26
-2
PHM
31
-11
MCD
44
-2
Financhill
Back

Avalo Therapeutics 10K Form

Sell
1

AVTX
Avalo Therapeutics

Last Price:
$5.10
Seasonality Move:
-21.62%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AVTX News And Ratings

See the #1 stock for the next 7 days that we like better than AVTX

AVTX Financial Statistics

Sales & Book Value

Annual Sales: $441K
Cash Flow: $-15M
Price / Cash Flow: 0
Annual Sales: $12.70
Price / Book: 0.44

Profitability

EPS (TTM): -3523.98770
Net Income (TTM): $-35.1M
Gross Margin: $807K
Return on Equity: -375.96%
Return on Assets: -34.97%

Avalo Therapeutics Earnings Forecast

Key Avalo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for AVTX is 182.99%.
  • The Selling, General & Administrative Expenses for AVTX have been equal to 3,909.52% of Gross Profit Margin.
  • The Research & Development expenses have been 11,809.07% of Revenue.
  • The Net Earning history of AVTX is -7,965.76% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 7 years.

Avalo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AVTX
Website: avalotx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 19.96
Quick Ratio: 19.42

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AVTX Technical Analysis vs Fundamental Analysis

Sell
1
Avalo Therapeutics (AVTX) is a Sell

Is Avalo Therapeutics a Buy or a Sell?